Yangzijiang Pharmaceutical Group (hereinafter referred to as Yangzijiang Pharmaceutical) was founded in 1971 and started in traditional Chinese medicine. In 1988, when hepatitis A was prevalent in Shanghai, 3.85 million packs of plate blue root dry syrup from Yangtze River Pharmaceutical Factory rushed to help people prevent and control the hepatitis A epidemic, and Xu Jingren, then director of the factory, won the title of "King of Plate Blue Root".
More than 50 years later, the original Yangtze River Pharmaceutical Factory has changed from an obscure small town-run factory to a large-scale enterprise with both Chinese and Western medicines, and from 2014 to 2019, it has topped the list of China's top 100 pharmaceutical industries for six consecutive years.
Xu Jingren, the founder of Yangzijiang Pharmaceutical, has a special love for the cause of traditional Chinese medicine, and has regarded the exclusive traditional Chinese medicine with good curative effect as a treasure all his life, adhered to the self-confidence of Traditional Chinese medicine culture, adhered to the integrity and innovation, and written self-improvement into the new journey of modernization of traditional Chinese medicine, leading the development of the industry.
The Group focuses on traditional Chinese medicine products
Cite the name of the medical prescription, to create an exclusive Chinese medicine product square
Excavating the treasure house of traditional Chinese medicine and developing famous doctors are a major feature of the development of traditional Chinese medicine in Yangzijiang Pharmaceutical. At a time when the momentum of enterprise development is good, Xu Jingren has a keen insight into the future dilemma of product homogenization.
How to achieve "product breakthrough"? Xu Jingren was exhausted for this. For a long time, many prescriptions of traditional Chinese medicine with remarkable efficacy have been in the hands of old experts and folk traditional Chinese medicine practitioners in the field of traditional Chinese medicine, and in Xu Jingren's view, these prescriptions are the "gold mine" for the development of new treatments for a variety of diseases. To this end, Xu Jingren has extensively mobilized academic and interpersonal networks to investigate and collect various information. In the end, Professor Tung Chee-hwa's spleen and stomach disease prescription, the "Taidou of Traditional Chinese Medicine", attracted his strong attention.
In order to visit Tung Chee-hwa, Xu Jing went north several times, "three Gu Maolu", and sincerely asked for medicine. At that time, from Taixing County in Yangzhou City to Beijing, it took several cars and trains to change, and the fastest time was more than 20 hours. Several meetings, several in-depth talks, "collision out of the spark", Xu Jingren's enthusiasm for revitalizing national medicine impressed Professor Tung Chee-hwa. Elder Dong angrily agreed and invested the prescription "Xiangsu Drink" for the treatment of stomach diseases into the research and development of modern Traditional Chinese medicine, so that it could better benefit the majority of patients with stomach diseases.
In 1993, Yangzijiang Pharmaceutical Factory successfully developed a national pure Chinese medicine new drug gastric Su granules according to the dedication of Professor Tung Chee-hwa of traditional Chinese medicine. The picture shows the scene of the press conference of gastric Su Chong agent of Yangzhou Yangzijiang Pharmaceutical Factory.
Nowadays, the formula of "Xiangsu Drink" has long been transformed into the exclusive Traditional Chinese medicine product "Gastric Su Granules" of Longfengtang, a subsidiary of Yangtze River Pharmaceutical Group. Since 1988 began research and development, in 1993 officially listed, gastric Su granules became the first exclusive variety with independent intellectual property rights, but also the first national new chinese medicine products since the promulgation of the national new drug policy, its advent has played a demonstration role in creating famous and excellent Chinese medicine. In the past 29 years on the market, gastric granules have significantly improved the quality of life of patients and benefited hundreds of millions of patients with stomach diseases by improving the efficacy of stomach bloating, stomach pain and other symptoms.
The program is full of eyes and goes forward. Taking clinical efficacy as the first goal, Chinese medicine masters and famous doctors helped Yangtze River Pharmaceutical to create an exclusive phalanx of traditional Chinese medicine products. Relying on Zhou Zhongying, Chao Enxiang, Fang Hesong, Zhang Zhenyu, Gao Pengxiang and other masters of traditional Chinese medicine and the clinical prescriptions of famous old Chinese medicine, a large number of modern Chinese medicine preparation products such as Baile Sleep Capsules, Double Flower Lily Tablets, SuHuang Cough Capsules, Xiang Peony Granules, Lianyu Burn Cream, Divine Comedy Consumption Oral Liquid have been developed successively, which show unique efficacy and clinical value in various therapeutic fields such as digestion, respiration, oncology, gynecology, pediatrics, and burn trauma.
The R&D of Chinese medicine continues to excavate and pass on the treasures of traditional Chinese medicine
Famous doctors are famous parties, famous parties are famous products. Many star products of Yangtze River Pharmaceutical came into being, and the annual sales of many single products have entered the "100 million yuan and billion yuan club". During the fight against the new crown pneumonia epidemic, Yangtze River Pharmaceutical has 4 varieties of traditional Chinese medicines listed in the recommended drug guidelines for epidemic prevention and control in more than ten provinces, which has played a positive role in protecting people's health.
For decades, adhering to the practice of attaching equal importance to inheritance and innovation has made the development of traditional Chinese medicine in Yangtze River Pharmaceutical find the right direction: focus on developing exclusive Chinese medicine products with good efficacy for difficult and complicated diseases, common chronic diseases and multiple diseases, and use modern technology to revitalize traditional Chinese medicine. With the continuous market recognition of the clinical efficacy of Yangzijiang Pharmaceutical's traditional Chinese medicine products, Xu Jingren firmly embedded the firm belief that "Chinese medicine is the treasure of the motherland's national medicine, and it must be carried forward", as well as his feelings of "pharmacizing for parents and pharmacizing for relatives", firmly embedded in the hearts of Yangtze River people.
Shouzheng innovation, promote the standardization and internationalization of traditional Chinese medicine
While continuously excavating and inheriting the treasures of traditional Chinese medicine, Yangtze River Pharmaceutical attaches great importance to the research and development of innovative chinese medicines. "Promoting the internationalization of Chinese medicine standards and mastering the discourse power of the Quality Standard System of Chinese Medicines has become one of the directions of Yangtze River Pharmaceutical." Xu Jingren clearly puts the innovation and development of Chinese medicine in the first place, and Yangzijiang Pharmaceutical has never stopped innovating and exploring practices on the modernization and internationalization of Chinese medicine.
Embrace the era of Industry 4.0 and transform to intelligence. Jiangsu Longfengtang Chinese Medicine Co., Ltd. strives to build the country's premier modern Chinese medicine intelligent factory. The picture shows the automatic feeding robot of Jiangsu Longfengtang Chinese Medicine Co., Ltd.
In order to promote the modernization of Chinese medicine, since 2014, Yangzijiang Pharmaceutical has integrated all the resources related to the Chinese medicine industry, made every effort to build the Longfengtang Chinese Medicine Industrial Park, focused on many pain points such as weak basic research, insufficient innovation ability, low quality controllable level and so on, and made new breakthroughs in the intelligent production of Chinese medicines in the aspects of the modernization of Chinese medicines, Chinese medicine tablets, extracts, preparations, and the internationalization of quality standards of Chinese medicines.
In order to strengthen the research and development strength of traditional Chinese medicine, Yangtze River Pharmaceutical established the Institute of Chinese Medicine in Taizhou headquarters in 2009, and set up the Institute of Chinese Medicine in Beijing, Nanjing and other places, and the R&D team of the Institute of Chinese Medicine is nearly 100 people. At the same time, it has worked closely with China Pharmaceutical University, Nanjing University of Chinese Medicine, China Academy of Chinese Medical Sciences, Shanghai University of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine and other well-known universities in China, and hired 4 academicians to provide research and development support. At present, there are nearly ten innovative drugs of traditional Chinese medicine under research, covering respiratory, skin, digestive and other therapeutic fields.
The Group's standardized planting base of 10,000 mu of skullcap in Fuping, Shaanxi.
In order to control the quality of Chinese herbal medicines from the source, Yangzijiang Pharmaceutical Has established 166 standardized planting bases for Chinese medicinal materials such as Banlan root, gardenia and astragalus in Shaanxi, Gansu, Sichuan, Chongqing, Xiang and other provincial medicinal material production areas in accordance with the requirements of the GAP norms promulgated by the state, with a planting area of more than 400,000 mu. Standardized management has been implemented from the seed resources of medicinal materials, the whole process control from the source of medicinal materials to the product has been realized, the overall quality standard system of Traditional Chinese medicines that meets the characteristics of the complex system of Traditional Chinese Medicines and the widely applicable quality standard system of Traditional Chinese Medicines has been innovatively constructed, and the quality standards and related guiding principles of Traditional Chinese Medicines adopted by the Chinese Pharmacopoeia and the international mainstream Pharmacopoeia have been established.
In terms of factory management, Yangtze River Pharmaceutical has gradually established a set of scientific and efficient management rules and regulations; in factory design, civil design, process design, and strive to catch up with the world's advanced level, comparable to the latest advanced pharmaceutical, food and tobacco industries at home and abroad; in terms of tooling equipment, a large number of leading the world's most advanced pharmaceutical equipment will be used.
One by one, the development design and change point to a great vision: "to build a smart factory, set up an industry benchmark - to speed up the internationalization of Yangtze River Pharmaceutical equipped with new kinetic energy."
Yangzijiang people forge ahead, bold exploration, in the modernization of traditional Chinese medicine, internationalization of a solid step - in 2015, Yangzijiang Pharmaceutical's ginkgo biloba leaf extract and ginkgo biloba leaf both passed the EU GMP certification, becoming the first ginkgo biloba extract and ginkgo leaf production enterprise to obtain EU GMP certification in China.
In 2016, he undertook the national standardization project of traditional Chinese medicine, and explored the establishment of quality transmission research and control standards throughout the entire industrial chain from the planting of medicinal materials to the production and circulation.
In 2017, Yangtze River Pharmaceutical participated in the project of "Creation and Application of International-oriented Overall Quality Standard System for Traditional Chinese Medicine", which won the second prize of the National Science and Technology Progress Award.
In 2018, after 7 years of research, the quality standards of 5 varieties such as Tateshina Aoba and Saffron Seed were established in advance and successfully entered into the European Pharmacopoeia. Among them, Tateshina Aoba is the first Chinese medicinal material variety to enter the European Pharmacopoeia in the mainland.
In 2018, the "National High-tech Industry Standardization Pilot project for intelligent manufacturing of Traditional Chinese Medicine Processes" was launched, and a series of standards for intelligent manufacturing of Traditional Chinese medicine processes were established to help the intelligent manufacturing transformation of the Traditional Chinese medicine industry.
In April 2020, the "Requirements for the Quality Risk Control System for Pharmaceutical Manufacturers" formulated was selected as a local standard in Jiangsu Province and began to be promoted and applied in the pharmaceutical industry in the province.
Don't forget your original intention, you have to be consistent. In recent years, Yangzijiang Pharmaceutical has played a leading role and the brand effect of traditional Chinese medicine, followed the law of the development of traditional Chinese medicine, and sought to "find another way" and be diligent in "building bridges and roads", and comprehensively inherited the core values of "high quality, benefiting the people, innovating and being the best" in enterprise construction, product construction and staff team construction. The corporate vision of "being the strongest and world-class pharmaceutical enterprise in China" is gradually becoming a reality.
High starting point layout, taking the road to great health as a model
Let the famous TCM practitioners "live" up;
Let Chinese medicine "fire" up in the world;
Let the people's healthy life be "good".
It is understood that Yangzijiang Pharmaceutical has always been guided by market demand, laid out the chinese medicine health industry from a high starting point, firmly grasped the efficacy and quality advantages of proprietary Chinese medicines, and continued to cultivate in the field of Chinese medicine health. "To be a good inheritor of Chinese medicine culture, to be a good health gatekeeper, and to effectively inherit, develop and make good use of the precious wealth left to us by the ancestors of Chinese medicine is the unswerving original mission of Yangtze River Pharmaceutical." Xu Haoyu, secretary of the party committee, chairman and general manager of Yangtze River Pharmaceutical, said.
Under the guidance of the Healthy China Strategy, Yangtze Jianglongfengtang will continue to adhere to the core advantages of proprietary Chinese medicines, create a number of chinese medicine blockbuster products, continue to carry out the standardization and international exploration of Chinese medicines, strengthen the maintenance of international intellectual property rights of Chinese medicine products, strengthen the inheritance and research of the core technology of Chinese medicine processing, synchronize with the international standards for the control of heavy metals, pesticide residues and microorganisms of drugs, always face the forefront of scientific and technological innovation, and actively open up new channels and new markets for food and health products.
Innovation is difficult, struggle to succeed. Generation after generation of Yangtze River people adhering to the ideal pursuit of revitalizing traditional Chinese medicine, with the responsibility of "protecting all sentient beings", has been committed to finding traditional Chinese medicine products with excellent clinical efficacy, not afraid of resistance, dare to think and dare to break through, after the baptism of years, the precipitation of time, the verification of clinical efficacy, cast into the Yangtze River Pharmaceutical "pyramid" of traditional Chinese medicine.
The vast east wind rises flat, just when the full sails are fast forward. In the future, Yangtze River Pharmaceutical will take a new attitude and stride forward towards "world-class pharmaceutical enterprises"!